Request Demo

Last update 08 May 2025

gp100 x TYR

Last update 08 May 2025

Basic Info

Related Targets

gp100TYR

Drugs associated with gp100 x TYR

Multi-epitope peptide melanoma vaccine(University of Pittsburgh Medical Center)

Target

MAGEA1 x TYR x gp100

Mechanism

MAGEA1 modulators [+2]

Active Org.-

Originator Org.

University of Pittsburgh Medical Center

Active Indication-

Inactive Indication

Melanoma

Drug Highest PhasePending

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Autologous mRNA-electroporated dendritic cell vaccine (Radboud University)

Target

TYR x gp100

Mechanism

TYR modulators [+1]

Active Org.-

Originator Org.

Radboud University Nijmegen

Active Indication-

Inactive Indication

Uveal Melanoma

Drug Highest PhasePending

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with gp100 x TYR

100 Translational Medicine associated with gp100 x TYR

0 Patents (Medical) associated with gp100 x TYR

580

Literatures (Medical) associated with gp100 x TYR

01 May 2025·The American Journal of Dermatopathology

Melanoma With RNF11::BRAF Fusion: A Novel Fusion Previously Undescribed in Melanoma

Article

Author: Curry, Jonathan L. ; Torres-Cabala, Carlos A. ; Yang, Richard K. ; Gao, Yan ; Cho, Woo Cheal

Abstract:B-Raf Proto-Oncogene (BRAF) fusions are rare in melanomas. We present a case of cutaneous melanoma with a Ring Finger Protein 11 (RNF11)::BRAF fusion in a 63-year-old man with a history of stage IB melanoma on the right upper back (pT2apN0cM0; nonulcerated with a Breslow thickness of 1.2 mm). Despite initial treatment, the melanoma progressed to multiple metastases. Histopathologically, the tumor cells exhibited epithelioid and rhabdoid morphologies, with occasional giant pleomorphic cells and multinucleation, and were positive for antimelanocytic cocktail (HMB45, Melan-A, tyrosinase) and S100. Next-generation sequencing of a metastatic specimen identified an RNF11::BRAF fusion and TERT promoter mutation, but no other somatic mutations (eg, BRAF, NRAS, KIT) or copy number variations were detected. The patient died to melanoma approximately 58 months after initial diagnosis, despite several lines of systemic therapy, including immunotherapies and a mitogen-activated protein kinases 1 and 2 inhibitor. RNF11::BRAF fusions are known oncogenic drivers in histiocytic disorders such as Erdheim–Chester disease and non-Langerhans cell histiocytosis. Although BRAF fusions are commonly observed in Spitz melanocytic neoplasms, the discovery of the RNF11::BRAF fusion in melanomas is unprecedented. Our case represents a triple wild-type, clinically aggressive melanoma of possibly non-Spitz lineage with an ultraviolet signature and a rare BRAF fusion, contributing to the expanding body of literature on BRAF-fused melanomas.

01 May 2025·Journal of Cutaneous Pathology

Spitz Spindle Cell/Reed Nevus With SQSTM1::NTRK2 Fusion and Atypical Features in an Older Male Patient: A Case Report and Review of Literature

Review

Author: Scarfò, Federico ; Brunetto, Emanuela ; Ferrara, Gerardo ; Pecciarini, Lorenza ; Rizzo, Nathalie ; Magliacane, Gilda

ABSTRACTSpitz lesions display a set of genetic alterations that differ from classical melanocytic lesions: examples include mutations in HRAS and fusions involving ALK, ROS1, MET, MAP3K8, BRAF, and the NTRK genes. We present a Spitz spindle cell/Reed nevus with atypical junctional features and an NTRK2 translocation in a patient of unusual age. The patient was a 61‐year‐old man with a pigmented brown flat 6 mm lesion growing on the skin over the left scapula. The lesion was composed of spindled and epithelioid melanocytes and was arranged in nests with some scattered focal pagetoid cells as well as intraepidermal nests at the center of the lesion and occasional mitotic figures. The melanocytes showed diffuse staining for pan‐Trk antibodies. p16 staining was focally and weakly positive. The cells showed staining for HMB‐45, MART‐1, and tyrosinase, whereas they were negative for PRAME, ALK‐1, and ROS‐1 immunostaining. BAP‐1 was preserved. Next‐generation sequencing detected a SQSTM1::NTRK2 fusion and showed no alterations of ALK, ROS1, RET, NTRK1, and NTRK3 genes, as well as no pathogenic variants of BRAF. Fluorescent in situ hybridization showed NTRK2 translocation in all melanocytes evaluated. This case presents a Spitz nevus with a rare translocation in an older patient.

01 Apr 2025·International Journal of Biological Macromolecules

Siamese crocodile serum hydrolysate peptides: Potent tyrosinase inhibitors and melanogenesis regulators for hyperpigmentation

Article

Author: Roytrakul, Sittiruk ; Taemaitree, Lapatrada ; Klaynongsruang, Sompong ; Jangpromma, Nisachon ; Daduang, Sakda ; Kwathai, Mintra

Melanin safeguards cells from UV radiation, while also giving them colour (pigmentation). However, excessive melanin production (hyperpigmentation) can cause unwanted side effects such as skin freckles and food browning. As a result, there is a desire to control and in particular reduce melanin production. This study aims to identify bioactive peptides derived from Crocodylus siamensis serum that inhibit tyrosinase, which is a key enzyme in melanin production. We demonstrate hydrolysis of Crocodylus siamensis serum produces peptides that are potent inhibitors of tyrosinase. We demonstrate that alkaline hydrolysis is the most effective method (IC₅₀ = 0.4323 ± 0.049 μg/μL) and use peptidomic analysis to identify two peptides, HG8 (HIVGRGAG) and RI10 (RNIKASHILI), that are as effective alone as the serum hydrolysate. Our results show that both peptides could inhibit cellular tyrosinase activity and reduce melanin accumulation by down-regulating the expression levels of MITF, TYR, TRP1 and TRP2, which are key regulators of melanogenesis. The peptides also reduce the expression levels of Rab27A, MLPH, Myosin Va, Rab17 and gp100, suggesting they suppress melanosome maturation and transport. Furthermore, both peptides show antioxidant properties in B16F10 cells. These findings hold significant promise for the development of tyrosinase inhibitory peptides as therapeutic agents for hyperpigmentation.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis